This narrative review (2026) examines placebo-controlled single-dose studies of MDMA (75 to 125 mg) in healthy volunteers and finds that it acutely increases mood, empathy, trust and prosocial feelings, while causing temporary memory impairment and modest declines in motor coordination and cognitive flexibility. It also notes that post-acute fatigue and low mood can occur, and that MDMA may complicate trial blinding and expectancy in psychotherapy studies.
MDMA's history spans military experimentation, recreational use, and clinical trials for PTSD treatment, reflecting both promise and controversy. While studies in heavy users suggested possible neurotoxicity, evidence remains inconclusive. Clinical trials show that one to three sessions of MDMA-assisted psychotherapy can alleviate PTSD symptoms, yet regulators have criticized inadequate reporting of (positive) adverse events. To clarify safety, this narrative review examines placebo-controlled single-dose studies in healthy volunteers, focusing on MDMA's acute and subacute effects on subjective state and neurocognitive function relevant to therapeutic applications. Single doses of 75-125 mg enhance mood, empathy, trust, arousal, and prosocial feelings through monoamine reuptake inhibition and release. Post-acutely, transient monoamine depletion may cause fatigue and low mood. During intoxication, MDMA transiently impairs memory encoding via increased 5-HT signaling and 5-HT2A activation but does not heighten suggestibility. Inhibitory control and executive function are largely preserved, while motor coordination and cognitive flexibility decline modestly. These effects vary with metabolism, immune response, drug interactions, and context, underscoring the need for personalized monitoring. It is inferred that, acutely, positive affect may enhance therapeutic alliance and openness as well as susceptibility to boundary violations; amnestic effects may support trauma processing by facilitating fear extinction and disrupting negative memory reconsolidation; whereas temporary reductions in attention and cognitive flexibility may call for structured, emotionally focused therapeutic settings. MDMA's distinct neurocognitive profile offers clinical promise but complicates trial design by compromising blinding and inflating expectancy, necessitating their quantitative assessments and inclusion of similar comparator drugs to ensure reliable evaluation of efficacy.
Papers cited by this study that are also in Blossom
Benzenhöfer, U., Passie, T. · Addiction (2010)
Passie, T., Benzenhöfer, U. · Journal of Psychoactive Drugs (2016)
Vegting, Y., Reneman, L., Booij, J. · Psychopharmacology (2016)
Roberts, C. A., Quednow, B. B., Montgomery, C. et al. · Neuroscience and Biobehavioral Reviews (2017)
MDMA has a long and controversial history, moving from early chemical synthesis and military interest to therapeutic experimentation and later recreational use. Earlier work in heavy Ecstasy users raised concerns about possible serotonergic neurotoxicity and subtle cognitive harms, but those findings were limited by cross-sectional designs, confounding, and uncertainty about whether changes reflected permanent damage or adaptation. At the same time, Phase II and Phase III trials of MDMA-assisted psychotherapy for PTSD suggested substantial symptom reductions, yet regulators have criticised the evidence base for issues including adverse-event reporting, durability of benefit, blinding, and expectancy bias. Ramaekers and colleagues therefore set out to summarise placebo-controlled single-dose studies of pharmaceutical MDMA in healthy volunteers, with a focus on acute and subacute subjective effects and neurocognitive effects that are relevant to therapeutic use. Their aim was to identify what MDMA does in controlled clinical settings, what factors modify its effects, and what these findings imply for safety, trial design, and MDMA-assisted psychotherapy. The paper is framed as a narrative review intended to bridge mechanistic findings from healthy volunteers with clinical considerations for PTSD treatment.
This paper is a narrative review based on PubMed. The authors included clinical trials published between 1998 and 2025 that examined acute effects of MDMA in healthy volunteers, focusing on subjective and affective experience, cognitive and psychomotor function, and moderating factors such as immune response, genetic variation in MDMA metabolism, concomitant drugs, and sleep loss. The review prioritised placebo-controlled single-dose studies using pharmaceutical MDMA, generally in the 75-125 mg range or around 1.5-1.7 mg/kg body weight. The rationale was that these studies are more informative for therapeutic applications than cross-sectional studies of recreational users because they better isolate direct drug effects from long-term use patterns and polydrug exposure. The extracted text does not describe a formal systematic review search strategy, study selection process, or risk-of-bias assessment. Across the sections, the authors organised findings by domain: subjective and affective experience, memory, executive control, attention and psychomotor function, neuroimmune effects, drug and contextual interactions, and individual sensitivity and response variability. They also used mechanistic findings, including receptor blockade and pharmacological challenge studies, to infer which neurotransmitter systems contribute to MDMA's effects and how those effects might matter in psychotherapy.
The review reports that single clinical doses of MDMA reliably produce acute subjective effects that participants generally experience as positive. These include bliss, elevated mood, emotional empathy, trust, sociability, arousal, openness, and feelings of unity, with perceptual changes being relatively limited compared with classic psychedelics. In pooled data from six placebo-controlled within-subject studies (n = 118), MDMA 75 mg and 125 mg increased emotional empathy on the Multifaceted Empathy Test, particularly for positive emotions, without affecting cognitive empathy. Mechanistic studies suggest that these subjective effects are driven mainly by serotonin and noradrenaline transporter blockade, with additional contributions from 5-HT2A and, to a lesser extent, dopamine-related mechanisms. Pretreatment with SSRIs such as citalopram, paroxetine, or fluoxetine reduced many of MDMA's subjective effects, duloxetine also markedly reduced entactogenic and empathogenic effects, and haloperidol reduced positive mood. By contrast, 5-HT1A antagonism and adrenergic modulation had little effect. The review also notes that MDMA-related oxytocin increases were not clearly linked to empathy or subjective experience. The authors state that occupancy data and downstream biochemical markers remain limited. For memory, the review reports consistent but transient impairments during intoxication. MDMA disrupted verbal learning, immediate and delayed recall, spatial memory, and prospective memory, with some effects linked to plasma concentration and altered brain activation. One week later, retrieval of words learned under MDMA remained impaired in one study, suggesting disruption of encoding during intoxication rather than a persistent general memory deficit. However, by the next day, performance typically returned to baseline. MDMA did not increase suggestibility in misinformation paradigms, and 5-HT2A blockade selectively prevented some verbal learning impairment. In executive control, attention, and psychomotor function, the overall pattern was mixed. Stroop interference and core inhibitory control were largely preserved, and some motor or tracking tasks improved, but attentional control, divided attention, trail-making, driving simulator performance, and complex psychomotor integration were often impaired. One on-road driving study found reduced weaving but also overshooting of reactions, and 22% of participants failed a Standardised Field Sobriety Test while under MDMA. The review interprets this as relative preservation of simpler executive processes alongside reduced flexibility and attentional capacity. Neuroimmune studies in small male samples indicated that acute MDMA can alter immune markers, including reductions in CD4⁺ T-helper cells and lymphocytes, increased NK cells, and shifts towards a Th2/anti-inflammatory cytokine profile. Repeated dosing prolonged these effects. Pretreatment with paroxetine attenuated several immune changes, suggesting a serotonergic contribution. The review also reports that combining MDMA with other substances or sleep loss generally increases risk. With alcohol, cannabis, LSD, or methylphenidate, MDMA often worsened objective performance or cardiovascular strain despite subjective alertness or positive mood. Alcohol and cannabis increased cardiovascular and cognitive risks; LSD exposure was prolonged; methylphenidate intensified hemodynamic and adverse effects; and sleep deprivation worsened memory, divided attention, and driving performance despite reduced subjective sleepiness. Genetic and sex differences were also reported: polymorphisms in CYP2C19, CYP2B6, and CYP1A2 influenced MDMA metabolism and cardiovascular response, women often showed stronger subjective effects and greater CYP2D6 inhibition, and adverse and cardiovascular effects were dose-dependent and more frequent in women. Overall, the review presents MDMA as producing a distinctive profile of enhanced empathy, trust, and emotional openness alongside temporary memory impairment, some attentional and psychomotor disruption, and possible immune and cardiovascular effects. These findings are described as relevant to clinical use because they may shape therapeutic engagement, safety monitoring, and trial design.
The authors argue that the healthy-volunteer literature shows a consistent acute MDMA profile that is likely to be therapeutically relevant but also potentially risky. In their view, the most important positive features are heightened empathy, trust, openness, and emotional engagement, which could strengthen the therapeutic alliance and facilitate trauma-focused psychotherapy. At the same time, these same effects may increase vulnerability to boundary violations, dependency, or other ethical problems, so strict safeguards are needed. Ramaekers and colleagues emphasise that transient memory impairments may be relevant to PTSD treatment. They suggest that MDMA could help trauma processing by facilitating fear extinction, shifting emotional valence towards a more positive bias, or altering reconsolidation of traumatic memories. However, they stress that this remains a hypothesis and that studies in PTSD patients are still needed to determine whether these memory effects are therapeutic mediators or unwanted adverse effects. They also note that MDMA-assisted psychotherapy trials have not systematically measured intoxication-phase neurocognitive effects, abuse potential, or some adverse events to a level that satisfies regulators. The review positions these findings against earlier concerns about neurotoxicity and recreational Ecstasy use. The authors state that the available controlled studies in healthy volunteers do not support a claim of lasting memory damage after a single dose, although acute impairment during intoxication is clear. They also note that some neuroimmune changes, sex differences, and gene-related variability suggest that response is not uniform and may be influenced by metabolism, context, co-medication, sleep loss, and individual biology. Key limitations highlighted in the discussion include the reliance on healthy-volunteer studies rather than patient studies, the lack of direct links between laboratory cognitive effects and clinical outcomes, small samples in some mechanistic and immune studies, and incomplete pharmacokinetic-pharmacodynamic data. The authors also point out that MDMA's distinctive subjective profile makes blinding difficult, which can inflate expectancy effects and bias efficacy estimates. They therefore recommend quantitative measurement of blinding and expectancy, active comparator drugs where appropriate, careful screening for interactions, and potentially more personalised dosing strategies informed by sex and genotype. Their broader implication is that MDMA may have a useful but double-edged therapeutic profile that requires careful control, monitoring, and trial design.
MDMA blocks SERT, noradrenaline (NET) and dopamine (DAT) transporters in descending order. MDMA enters monoaminergic neurons to inhibit vesicular monoamine transporters (VMAT), allowing monoamines to accumulate in the cytosol. This leads to a reversal of transporter flow and a substantial release of these neurotransmitters, especially serotonin, into the extracellular space. Subjective effects of MDMA, including elevated mood, self-confidence, extraversion, and enhanced sensory perception, are largely mediated by SERT and NET, as they can be markedly reduced by SSRI pretreatmentor combined serotonergic/noradrenergic reuptake inhibitors. In addition, MDMA has been shown to bind with modest affinities to adrenergic, muscarinic, dopaminergic (e.g. D2), serotonergic (e.g. 5-HT1A, 5-HT2A) and histaminergic receptors. Dopaminergic and adrenergic activations by MDMA are primarily responsible for mediating acute sympathomimetic effects such as elevated blood pressure, heart rate and body temperature, bruxism and insomnia that are common after MDMA at doses between 75-150 mg. MDMA has also been demonstrated to increase oxytocin levels, presumably through activation of presynaptic 5-HT4 receptors. The oxytocinergic effect may reopen an age-related closure of a critical period of neuroplasticity that temporarily increases social reward learning, and increases feelings of trust and connectedness. After MDMA administration, tmax is attained at 2 h, while the elimination half-life of MDMA ranges between 8-9 h at doses between 50-125 mg. MDMA is metabolized via two pathways. In the major pathway, MDMA is dealkylated by the cytochrome (CYP) P450 isoform 2D6 to form the 3,4-dihydroxyamphetamine (DHA), which in turn is O-methylated into 4-hydroxy-3methoxymethamphetamine (HMMA). In the minor pathway, MDMA is N-demethylated by CYP3A4 into 3,4-Methylenedioxyamphetamine (MDA).
Acute, placebo-controlled studies with MDMA have been scarce during a time when most of the scientific research on MDMA was directed towards the assessment of long-term, neurotoxic effects. The first placebo-controlled trial in which 1.7 mg/kg of MDMA was administered to drug-naïve, healthy volunteers to examine its psychological effectsfaced immediate criticism over ethical concerns regarding potential long-term serotonergic damage. However, alterations in neuronal 5-HT availability observed after a single MDMA dose do not necessarily indicate serotonergic neurodegeneration. Moreover, a single dose of MDMA (1.5 mg/kg, PO) in (a pilot study with) healthy volunteers did not change serotonin transporter density in cortical and subcortical brain regions using PET and [C-11](+)McN-5652 at one-month follow-up compared to baseline and placebo controls. Acute studies with MDMA are therefore safe and essential to clarify the subjective profile, mechanisms and consequences of MDMA intoxication. Since then, an increasing number of acute MDMA studies in healthy volunteers have been conducted worldwide to assess the acute and subacute pharmacokinetics and pharmacodynamics of MDMA, at doses ranging between 75-125 mg. In the early days, around the start of the 21st century, the majority of acute MDMA research came from four research labs that focused on pharmacokinetics and safety (IMIM, Barcelona), mechanism of action, brain function, neurocognition and psychological experience (University of Zurich, Maastricht University and University of Chicago). These early studies served as an intermediate between cross-sectional research on long-term neurotoxicity and later initiatives to develop MDMA as an adjunct to psychotherapy in the treatment of PTSD. That is, acute MDMA studies in healthy volunteers have alleviated concerns about MDMA-induced neurotoxicity, while providing safety data necessary to offset therapeutic research. The following sections review evidence from studies in healthy volunteers on the acute subjective and neurocognitive effects of MDMA since the first landmark trialand discuss their potential implications for MDMA's therapeutic use. This narrative review was conducted using PubMed and included clinical trials published between 1998 and 2025 that investigated the acute effects of MDMA on subjective and affective experience, cognitive and psychomotor function, as well as moderating factors such as immune response, genetic variation in MDMA metabolism, and interactions with concomitant drugs and sleep loss. Moderating factors were incorporated because they may identify key considerations for inclusion and exclusion criteria, as well as for safety monitoring procedures, in clinical protocols investigating MDMA within patient populations. A summary of key findings from this narrative review is provided in Table.
MDMA increases feelings of a blissful state, experience of unity and changed meaning of percept in a dose-dependent manneras rated with the 11-factor version of the Altered States of Consciousness questionnaire (11D-ASC), as shown in Fig.. Perceptual alterations are minimal, distinguishing it from classic psychedelics. MDMA-induced changes in ratings of ASC have been associated with changes in underlying brain network integrityand subjective liking. Subjective effects of MDMA that are rated or self-reported across healthy volunteer trials include a wide range of desired effects (Fig.). A pooled analysis of six placebo-controlled within-subject trials (n = 118) revealed increased emotional empathy at MDMA 75 and 125 mg in the Multifaceted Empathy Test (MET), without affecting cognitive empathy. This MDMA-related increase in empathy was most pronounced when presenting positive emotions as compared with negative emotions. Reports of enhanced emotional empathy, positive mood, increased sociability, increased trust, opennessand heightened arousalafter single doses of MDMA can be found across a wide range of studies. More specifically such reports include enhanced pleasantness of social touch, attentional bias toward positive expressions of emotions, increased fear extinction and reduced recognition of negative emotions, increments in closeness to self or others, increased emotional expressionand increased prosocial decision making. However, subjective reports of prosocial effects of MDMA cannot always be confirmed with objective measures of trust or empathy. Observations that MDMA increases trust and prosocial behavior often draw on subjective reports and may thus be vulnerable to expectancy effects and contextual framing. Alterations in subjective and affective experience under MDMA have largely been attributed to the MDMA induced increments of monoamine release. Mechanistic investigations employing SERT and NET blockade prior to MDMA administration have consistently demonstrated attenuation of its subjective effects. Blockade of SERT through pretreatment with citalopram, paroxetine or fluoxetine reduced the overall effects of MDMA (100 mg and 1.5 mg/kg) on 11D-ASC ratings (e.g. blissful state, experience of unity), moodand subjective experience. Blockade of NET attenuated some, but not all, of the psychotropic effects of MDMA and reduced the overall rating of the 11D-ASC. Blockade of both SERT and NET by duloxetinerobustly reduced the effect of MDMA 125 mg on the total 11D-ASC score and reduced or prevented entactogenic and empathogenic effects. Of note, pretreatment with bupropion, a NET-DAT inhibitor, increased the subjective effect of MDMA 125 mg. Beyond promoting 5-HT and noradrenaline release, MDMA may also exert psychotropic effects through indirect stimulation of 5-HT2A receptors. Blockade of 5-HT2A receptors reduced the effects of MDMA (75 mg) on positive mood, arousal to negative sounds, emotional excitation and changed meaning of percepts in the 11D-ASC, and reduced adverse effects such as restlessness and inner tension on the List of Complaints (CL) scale. Pretreatment with the D2 antagonist haloperidol also reduced MDMA-induced positive mood but did not affect other subjective effects of MDMA (1.5 mg/kg). MDMA-induced functional connectivity changes in 5-HT2A-enriched maps also correlated with changes in subjective state as measured with the 11D-ASC. Subjective effects of single doses of MDMA were hardly affected by pretreatments with 5-HT1A antagonistsand adrenergic (α1, α2) receptor modulators. Likewise, MDMA induced increments in oxytocin were not associated with MDMA (1.5 mg/kg) induced alterations in empathy or subjective experience under MDMA. Although mechanistic work has highlighted the role of monoamine transporters and receptors in shaping the subjective effects of MDMA, corresponding occupancy data are still lacking, limiting a more detailed understanding of the pharmacokinetic-pharmacodynamic relationships involved. Likewise, mechanistic studies have not identified downstream biochemical changes that would be necessary to capture the full range of neural processes underlying the subjective and affective effects of MDMA. Most mechanistic studies have also centered on subjective experience and mood, without incorporating behavioral measures of empathy, trust, or prosocial behavior, which may constrain the generalization of their mechanistic conclusions to these domains.
The subjective effects of MDMA may play a central role in MDMAassisted therapy as these create a psychological state, i.e., trust, empathy and emotional openness, that directly supports the therapeutic processSubjective feelings of anxiety and loss of control are usually low, which contributes to MDMA's therapeutic tolerability. Together, these effects of MDMA may provide a therapeutic window in which trauma can be explored, reframed, and integrated, laying the groundwork for lasting symptom relief]. Yet the extent to which MDMA interacts with psychotherapy or contributes to therapeutic outcomes in the treatment of PTSD is still largely unknown, and future clinical trials are needed to parse their respective contribution. MDMA-assisted therapy also entails safety risks that require proactive management, as participants may be particularly vulnerable in altered states of consciousness. An example is the use of therapeutic touch within this context, that has triggered an ongoing debate regarding its therapeutic value relative to its risks. Similar concerns include an increased vulnerability to boundary violations such as sexual abuse, as well as the development of interpersonal dependency. Finally, while MDMA commonly produces acute enhancements in mood and affect, these may later reverse into mild, temporary adverse experiences during the sub-acute phase, a phenomenon that may reflect underlying monoamine depletion. Subacute adverse effects such as anhedonia, fatigue and lack of energy have been reported in context of recreational Ecstasy users [105, 107] and in clinical trials in healthy volunteers, and potentially may occur in patients treated with clinical doses of MDMA as well.
Ecstasy is often claimed to cause neurotoxic impairment of shortand long-term memory, based on cross-sectional comparisons between recreational users and non-users. Because such studies cannot establish causality, a prospective longitudinal study was conducted to address this limitation. The study monitored performance on 5 memory tasks in Ecstasy naïve subjects with high risk of Ecstasy use at baseline and over a period of 3 years. Comparison of memory performance of individuals who turned to (minimal) Ecstasy use during that period with those who did not, revealed lower performance on a verbal learning task at the 3-year mark. The authors concluded that even a first, low cumulative dose of Ecstasy could impair verbal memory. However, this difference reflected improvement among non-users rather than decline in users, and all scores remained within normal ranges. Thus, the study's findings were likely overinterpreted and did not substantiate a genuine memory deficit in novice Ecstasy users. Evidence that a single dose of MDMA does not cause lasting memory impairment had already been provided in placebocontrolled clinical trials in which verbal word learning and spatial memory performance was assessed in healthy volunteers between 1-2 h and 25-26 h after a single dose of. The findings demonstrated temporary deficits in immediate and delayed verbal recall, along with impairments in spatial memory, following MDMA during encoding. By the next day, both verbal learning and retrieval of new words and spatial memory performance had returned to baseline. A pooled analysis of verbal memory performance in 64 healthy volunteers (limited experience with Ecstasy) who participated in clinical trials further confirmed that memory impairment only occurred during active treatment with MDMA 75 mg and not during placebo, when compared to a matched group of non-drug using healthy volunteers. More studies have demonstrated that acute MDMA intoxication induces memory impairments. MDMA 75 mg induced prospective memory deficits [116] and encoding deficits during word learningthat were positively correlated to MDMA concentrations in plasma, and that could be directly linked to altered BOLD activation in thalamic, parietaland frontalregions of the brain. A single dose of MDMA 100 mg during encoding impaired immediate recall in a verbal learning task. MDMA 75 mg during encoding of associated word lists impaired retrieval of correct words but did not increase sensitivity to suggested memories for false words or false events in misinformation paradigms. One week later, retrieval remained impaired for words learned under MDMA intoxication, suggesting that MDMA primarily disrupted the initial encoding of words during intoxication. Healthy volunteer studies thus generally indicate that the acute impairing effect of MDMA on memory are short-lived. Still, it is unclear whether prolonged, next-day memory impairment might develop in susceptible individuals, including the elderly, or at higher doses. The pharmacological mechanism underlying MDMA-induced memory impairment is likely to be related to 5-HT release rather than dopamine release as methylphenidate, a NET-DAT inhibitor, did not induce memory impairment in a direct comparator study with. Some of the acute memory deficits may even be related to (indirect) stimulation of the 5-HT2A receptor as demonstrated in a placebo-controlled study in which participants received a single dose of MDMA 75 mg with or without 5-HT1A or 5-HT2A receptor blockers. MDMA significantly impaired verbal learning, spatial and prospective memory. Pretreatment with a 5-HT2A receptor blocker selectively prevented MDMAinduced impairment of verbal learning, but not of spatial and prospective memory. Pretreatment with a 5-HT1A blocker did not affect MDMA induced memory impairment. MDMA induced memory impairments did not change after blockade of MDMA induced cortisol increase [119] or after pretreatment with a NMDA antagonist.
It has been argued that amnestic effects of MDMA during acute exposure may be beneficial for fear extinction and reconsolidation of traumatic memories in the treatment of PTSD. Clinical trials in healthy volunteers have in part supported this notion. Acute exposure to MDMA 125 mg facilitated rapid fear extinction in experimental paradigms, whereas a single dose of 100 mg did not. Other studies have reported that MDMA (1 mg/kg) impaired encoding and retrieval of details of emotional memories while not affecting the overall accuracy of recollection. Healthy volunteers who received MDMA 100 mg reported that positive autobiographical memories became more vivid and emotionally positive, while bad memories were rated as less negative. Functional MRI data in that same study revealed that MDMA augmented activations to positive memories in the fusiform gyrus and somatosensory cortex and attenuated activations to negative memories in the left anterior temporal cortex, suggesting that MDMA induces a positive emotional bias. Overall, current data in healthy volunteers suggest that MDMA exposure might interfere with the reconsolidation of traumatic memory either by inducing a positivity bias and fear extinction, or through impairment of emotionally salient aspects of a traumatic experience. Importantly, while MDMA-assisted psychotherapy in PTSD relies heavily on trust and openness between patient and therapist when revisiting, destabilizing, and reprocessing traumatic experiences, current findings from misinformation Fig.Subjective effects of MDMA. A shows alteration in state of consciousness after single doses of MDMA (adapted from). B shows a circular map of subjective effects that are frequently reported after a single dose of MDMA (75-125 mg) in placebo controlled clinical trials in healthy volunteers. paradigms in healthy volunteers suggest that recognition memory is not more vulnerable to suggestive pressure during or after MDMA intoxication. Still, clinical trials in individuals with PTSD are needed to clarify whether MDMA-related alterations in memory processes influence fear extinction and the reconsolidation of traumatic memories, and how these effects may contribute to symptom improvement.
Experimental studies in healthy volunteers have shown that acute MDMA administration (75-125 mg or 1.7 mg/kg bodyweight) affects a range of cognitive domains, with effects varying across tasks and doses. To systematize the diverse measures used across studies, we clustered tasks into major cognitive domains: executive control, attention and psychomotor function. This framework allows integration of findings across heterogeneous paradigms, that in part also assess interdependent constructs. Executive domains were tested with the Stroop task, Tower of London, word fluency, two-choice prediction and numerical tasks. Stroop interference was unaffected, while performance on motor and cognitive impulse tasks improved under MDMA, indicating preserved or slightly improved inhibitory controlStudies on attention and vigilance employed neurocognitive tasks such as digit vigilance, visual search, divided attention, and signal detection probing sustained and selective attention and generally showed mixed findings. One study reported improved tracking performance under divided attention conditions [127], suggesting MDMA may transiently enhance performance when tasks involve psychomotor tracking. However, impairment of trailmaking task performance following a single MDMA dose has also noted, reflecting reduced attentional control. Psychomotor tasks included reaction time, motor choice reaction, and continuous tracking. Simple reaction time findings showed overall no effects of MDMA; however, after repeated dosing, there was a decrease in performance compared to placebo when 100 mg of MDMA was followed by the same dose after 4 h [133], but not when 50 mg was followed by 100 mg, 2 h later. MDMA was associated with faster movement times in a motor choice reaction task. Similarly, tracking performance improved under MDMA [127], perhaps reflecting increased alertness. Enhanced tracking ability was also observed in an on-road driving task, where participants showed reduced weaving while under the influence of MDMA. Other aspects of driving were influenced negatively by MDMA, as demonstrated by an overshooting of reactions. Also, in a driving simulator, impairments were consistently observed, and on a Standardized Field Sobriety Test, 22% of the sample failed when under the influence of MDMA. Tasks tapping perceptual gating and prediction (e.g., pre-pulse inhibition, object movement estimation) revealed specific alterations. MDMA enhanced pre-pulse inhibition (PPI) [135], consistent with increased sensorimotor gating. In contrast, object movement estimation was impaired under divided attention [127], suggesting disruptions in spatiotemporal prediction when cognitive load is high. Implications for therapeutic use Across domains, MDMA shows a pattern of relative preservation of inhibitory control and executive function, occasional facilitation of motor tracking and attention, but consistent impairments in complex psychomotor integration and cognitive flexibility. These effects likely reflect MDMA's combined serotonergic, noradrenergic and dopaminergic actions, producing heightened arousal and rigid behavioral strategies at the expense of adaptive control. Taken together, the available evidence suggests that MDMAassisted therapy may benefit from a window of preserved executive function and impulse control, combined with altered emotional and perceptual processing. Yet, therapists should be mindful of reduced flexibility and attentional lapses during intoxication, tailoring the therapeutic environment to support focused, emotionally guided work while avoiding tasks that require rapid adaptation or divided attention. To date, there are no data demonstrating that acute MDMArelated changes in laboratory indices of executive function are associated with symptom reduction in patients with PTSD. However, MDMA-assisted psychotherapy has been reported to produce lasting increases in the personality trait openness, a construct related to cognitive flexibility, which were associated with reductions in PTSD.
Stress is known to disrupt immune function and immune cell distribution, and MDMA acts as a chemical stressor. Experimental studies in healthy men show that acute MDMA administration (75-100 mg) induces time-dependent immune dysfunction, although these findings were derived from small, male-only samples conducted within a single laboratory [137-140]. Acute effects include reduced CD4⁺ T-helper and mature T lymphocytes, a lowered CD4/CD8 ratio, increased natural killer (NK) cells, and a shift in cytokine signaling from Th1 (IL-2, IFN-γ) toward Th2 cytokines (IL-4, IL-10), along with increased TGF-β [137-140]. Repeated dosing (two 100 mg doses, 4-24 h apart) prolongs these effects, with immune suppression detectable up to. Longitudinal data from recreational users further suggest persistent immune dysregulation, marked by declining lymphocyte counts and increased infection susceptibility. These immune changes appear to reflect both direct pharmacological effects of MDMA and its neuroendocrine consequences. MDMA increases cortisol and prolactin and promotes an antiinflammatory/Th2 cytokine profile. Pretreatment with the SSRI paroxetine attenuated MDMA-induced immune alterations, including reductions in CD4⁺ T-helper cells, lymphocyte responsiveness, and increases in NK cells and anti-inflammatory cytokines [141], indicating partial mediation via serotonergic mechanisms interacting with stress-pathways.
For therapeutic contexts, this means that MDMA may dampen cell-mediated immunity which suggests the need for clinical monitoring in vulnerable populations (e.g., those with compromised immune function) and consideration of timing, dosing, and frequency of administration to minimize immune risks while leveraging MDMA's psychotherapeutic benefits.
The interactions of MDMA with alcohol, cannabis, LSD, methylphenidate, and sleep loss have been examined in placebocontrolled human studies. Overall, while MDMA acutely increases arousal and vigilance, it rarely improves and often worsens objective neurocognitive performance and safety during combined exposures. Although MDMA alone could improve neurocognition and performance, it did not fully offset alcohol-induced impairment. Despite this, individuals often felt more alert under MDMA plus alcohol than their actual performance indicated, increasing overconfidence risk. EEG findings support this dissociation, with alcohol increasing low-frequency oscillations and MDMA reducing them, while their combination produced distinct cortical patterns without restoring executive control. Alcohol also increased MDMA plasma concentrations (~13%), highlighting a hazardous mismatch between subjective and objective effects. Combined MDMA and cannabis use additively increased heart rate, prolonged hyperthermia, and exacerbated cognitive impairment, with corresponding EEG interaction patterns. Co-administration with LSD prolonged LSD's subjective effects via pharmacokinetic alterations (↑Cmax, ↑AUC, longer t½), but did not improve subjective quality or reduce adverse effects. MDMA combined with methylphenidate did not show pharmacokinetic interactions, yet produced greater hemodynamic responses and adverse effects than either drug alone. While MDMA enhanced positive mood and methylphenidate increased activity and concentration, their combination amplified cardiovascular strain without additive benefit. Under sustained wakefulness, MDMA transiently reduced subjective sleepiness and slowed attentional decline [147, 148], but progressive sleep deprivation led to a worsening of memory, divided attention, and driving performance. Thus, MDMA's stimulatory effects may mask fatigue but do not prevent neurocognitive deterioration during prolonged sleep loss.
For therapeutic applications, MDMA should be administered under carefully controlled conditions, as co-use with other substances consistently increases risk without enhancing benefit. Overall, effective MDMA-assisted psychotherapy requires abstinence from interacting, psychoactive substances, adequate rest, and close medical/drug screening to ensure safety and support therapeutic efficacy.
Several studies have examined how genetic variation influences MDMA's pharmacokinetics and subjective effects. Pooled analyses show that polymorphisms in CYP2C19, CYP2B6, and CYP1A2 affect MDMA metabolism to its active metabolite MDA, with CYP2C19 poor metabolizers exhibiting stronger cardiovascular responses. Beyond metabolism, genetic variation in serotonergic and oxytocin systems has been linked to modulation of acute and socio-emotional effects, although some associations lost significance after correction for multiple comparisons. Overall, pharmacokinetic and pharmacodynamic genes contribute to inter-individual variability in MDMA responses, though effects are modest or inconsistent. Sex differences have also been reported. Women showed stronger subjective responses and greater CYP2D6 inhibition following MDMA, which may prolong exposure and intensify effects. However, similar plasma concentrations across sexes suggested that genetic polymorphisms, including 5-HTTLPR and COMT, rather than sex-based pharmacokinetics, underlie differences in cardiovascular and subjective effects. Finally, pooled data indicated that single MDMA doses (75-125 mg) are generally safe under controlled conditions, producing mainly positive subjective effects, though adverse and cardiovascular effects were dose-dependent and more frequent in women, warranting caution in vulnerable populations.
These findings underscore the need for personalized approaches in MDMA-assisted therapy. Since women and certain genetic subgroups may be more sensitive to MDMA's effects, sex and genotype should be considered in dose selection, monitoring, and safety planning. CYP2D6 inhibition further highlights the risks of repeated dosing or drug-drug interactions, while genetic variation in serotonin and oxytocin systems may influence the therapeutic "window" of prosocial and empathogenic effects, although potentially negligible. Incorporating sex-and genotype-informed strategies could improve both the efficacy and safety of MDMA in clinical contexts.
Acute studies of MDMA in healthy volunteers demonstrate that a single dose can alter subjective and affective experiences in ways generally perceived as positive. Participants frequently report feelings of bliss, elevated mood, heightened trust, empathy, and prosocial orientation. These effects, arising during intoxication through MDMA's blockade of monoamine reuptake and the resulting surge in serotonin, dopamine, and norepinephrine, can have therapeutic relevance. It is hypothesized that in clinical contexts, prosocial and mood-enhancing effects may strengthen the therapeutic alliance and foster openness to the therapeutic process. However, they also carry potential risks. The acute amplification of trust and emotional openness may increase vulnerability to boundary violations, requiring strict ethical safeguards. Moreover, because the monoaminergic surge is transient, it may be followed by a short-lived state of neurotransmitter depletion, manifesting as subacute anhedonia and fatigue. Thus, while MDMA's acute profile may offer unique opportunities for therapeutic engagement, it also necessitates vigilant monitoring to mitigate psychological and physiological risks. In this context, it is noteworthy that a major reason for the FDA's decision to decline approval of MDMA treatment was the failure of clinical trials of MDMA-assisted therapy for PTSD to adequately collect and report adverse events, including "positive or favorable" events relevant to the assessment of abuse potential, in addition to other methodological concerns such as limited durability data, functional unblinding, and expectancy bias. While future MDMA clinical trials should systematically capture adverse events, evidence from healthy volunteer studies shows that, with appropriate safeguards, 'positive' adverse events are transient and safe. MDMA carries a relatively low risk of dependence as it primarily is a serotonergic drug, with mild pro-dopaminergic and adrenergic properties. Animal studies show MDMA has weaker rewarding effects than other stimulant drugs and does not induce physical dependence in mice. Some patients in MDMA-PTSD trials reported subsequent ecstasy use; however, this use was primarily motivated by therapeutic intent rather than recreational abuse. Hence, expanding access to legal MDMA-assisted therapy could help prevent patients from turning to illicit ecstasy for therapeutic purposes. Nonetheless, future MDMA trials in PTSD patients will need to systematically assess signals of abuse potential to inform appropriate labeling and guidance for the safe use of MDMA. Similarly, clinical trials in PTSD patients have not systematically assessed neurocognitive impairments that may occur during the intoxication phase, even though such effects are important for accurately characterizing the drug in labeling and for guiding appropriate monitoring to ensure the safe use of MDMA. Healthy volunteer studies consistently demonstrated that MDMA affects neurocognitive function. MDMA's monoaminergic actions induced impairment of memory and cognitive flexibility, preserved inhibitory control and core executive functions, while inconsistently stimulating psychomotor speed and attention. The finding that MDMA attenuates the encoding and retrieval of salient details from emotional events, is consistent with the idea that its potential therapeutic effects for treating posttraumatic stress disorder are related to altering emotional memory. Therefore, the amnestic effects of MDMA as observed in healthy volunteers may, paradoxically, support processes in patients by facilitating reconsolidation of traumatic memories, either through a positivity bias and enhanced fear extinction, or by dampening the recall of emotionally salient aspects of trauma. However, this hypothesis still needs to be systematically tested in future MDMA trials with PTSD patients in order to be able to classify MDMA induced memory impairments as therapeutic mediators or unwanted adverse effects. Acute neurocognitive effects of MDMA are not uniform, but can be shaped by neurochemical and immune state, genetic makeup, sex, contextual co-factors, concomitant medication or substance use, which together may explain variability in both therapeutic and adverse outcomes. The presence of factors that can moderate the response to MDMA suggest that "personalized MDMA therapy" strategies may reduce some of this variation. Such strategies are still emerging and may include pharmacogenomics to select dose, control MDMA levels in blood, reduce adverse risk, and optimize therapeutic exposure. Other strategies might include flexible dosing (e.g. initial dose + optional booster) to adjust dosing and tailor an individual's response, as already applied in current clinical trials. Likewise, strict avoidance and monitoring of potential drug interaction, adequate rest during treatment days, and sexinformed strategies might be relevant to optimize dosing and efficacy while minimizing risks. The distinct neurocognitive profile of MDMA is both a therapeutic opportunity and a methodological challenge, as it makes MDMA treatments readily distinguishable from inert placebos, which potentially may undermine the integrity of comparative clinical trials. Expectancy-driven unblinding in MDMA trials might inflate effect sizes and obscure true drug effects, as participants' and therapists' beliefs about treatment assignment bias outcome measures. While complete blinding may be unattainable, adding quantitative measures of blinding and expectancy throughout the time course of clinical trials can mitigate expectancy-driven bias. Recent recommendations also include assessing the causes of unblinding and the use of statistical tools to adjust for bias when estimating treatment effect sizes of treatment effects in comparison to control conditions. Alternatively, there are compounds whose neurocognitive profile is similar to that of MDMA and that hence might be difficult to distinguish by patients or therapists who are involved in clinical MDMA trials. These compounds include cathinones such as mephedrone, 3-MMC and methylone that, in addition, also produce similar pharmacokinetics and physiological responses. All of these compounds increased subjective ratings of mood and stimulated psychomotor function in healthy volunteers trials [163-168], while mephedrone also induced transient memory impairment. Synthetic cathinones are structurally related to amphetamines and, to varying degrees, are monoamine transporter substrates that stimulate the release and inhibit the reuptake of monoamines. Likewise, psychedelic phenethylamines such as 2C-B and 2C-E have been shown to produce physiological and neurocognitive responses that overlap with those observed after MDMA [172-174] and hence may serve as suitable comparator drugs in MDMA trials. However, the pharmacological and neurocognitive overlap between these compounds may also come with a trade-off between the opportunity of full blinding and the risk that these comparator drugs might induce (partial) efficacy. Some of these compounds, such as methylone, have already been recognized for their efficacy in the treatment of PTSD. Some of the synthetic cathinones may also provide a lower empathogenic serotonergic drive as compared to MDMA, depending on their affinity for SERT, which arguably might lower the risk of boundary violations during substance-assisted psychotherapy. In conclusion, MDMA's acute effects of neurocognition create a double-edged profile: on one hand, enhanced trust, empathy, emotional openness, and altered memory processing which provides a unique therapeutic window that can strengthen alliance and facilitate trauma processing; on the other hand low capacity of cognitive flexibility, increased vulnerability in patienttherapist interaction, and subacute incidence of anhedonia and fatigue may raise ethical and safety concerns. The neurocognitive effects of MDMA can potentially be perceived as positive or negative adverse events that require systematic monitoring. Variability in neurocognitive responses to MDMA highlights the potential for personalized approaches to dosing and safety management. Finally, because MDMA's distinctive profile undermines blinding, future studies should adopt active comparators and / or rigorous expectancy measurements to ensure valid efficacy estimates.
Create a free account to open full-text PDFs.
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Montgomery, C., Roberts, C. A. · Experimental Neurology (2021)
Liechti, M. E., Baumann, C., Gamma, A. et al. · Neuropsychopharmacology (2000)
Dunlap, L. E., Andrews, A. M. · ACS Chemical Neuroscience (2018)
Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Kirkpatrick, M. G., Francis, S. M., Lee, R. et al. · Psychoneuroendocrinology (2014)
Hysek, C. M., Liechti, M. E. · Psychopharmacology (2012)
Straumann, I., Ley, L., Holze, F. et al. · Neuropsychopharmacology (2023)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Kirkpatrick, M. G., Delton, A. W., de Wit, H. et al. · Journal of Psychopharmacology (2015)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Papaseit, E., Pérez-Mañá, C., Mateus, J. A. et al. · Neuropsychopharmacology (2016)
Vizeli, P., Liechti, M. E. · PLOS ONE (2018)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)
Schmid, Y., Schmidt, A., Müller, F. et al. · International Journal of Neuropsychopharmacology (2017)
Bershad, A. K., Hsu, D. T., De Wit, H. · Journal of Psychopharmacology (2024)
Vizeli, P., Straumann, I., Duthaler, U. et al. · Frontiers in Pharmacology (2022)
Baggot, M. J., Kirkpatrick, M. G., Bedi, G. et al. · Journal of Psychopharmacology (2015)
Gabay, A. S., Carhart-Harris, R. L., Mazibuko, N. et al. · Scientific Reports (2018)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Dipasquale, O., Selvaggi, P., Veronese, M. et al. · NeuroImage (2019)
Hasler, F., Ludewig, S. · Journal of Psychopharmacology (2008)
Sessa, B. · Neuroscience Letters (2016)
Zeifman, R. J., Kettner, H., Ross, S. et al. · European Journal of Psychotraumatology (2024)
Agin-Liebes, G. I., Zeifman, R. J., Mitchell, J. · European Journal of Psychotraumatology (2025)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Colcott, J., Guerin, A. A., Carter, O. et al. · Neuropsychopharmacology (2024)
Kuypers, K. P. C., Ramaekers, J. G. · Journal of Psychopharmacology (2005)
Kuypers, K. P. C., Ramaekers, J. G. · Psychopharmacology (2006)
Kuypers, K. P. C., Theunissen, E. L., de Sousa Fernandes Perna, E. B. et al. · PLOS ONE (2016)
Kloft, L., Otgaar, H., Blokland, A. et al. · European Neuropsychopharmacology (2022)
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)
Maples-Keller, J. L., Norrholm, S. D., Burton, M. et al. · Journal of Psychopharmacology (2022)
Doss, M. K., Weafer, J. J., Gallo, D. A. et al. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D. et al. · International Journal of Neuropsychopharmacology (2013)
Ramaekers, J. G., Kuypers, K. P. C. · Neuropsychopharmacology (2005)
Downing, J. · Journal of Psychoactive Drugs (1986)
Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2017)
Vizeli, P., Schmid, Y., Prestin, K. et al. · European Neuropsychopharmacology (2017)
Vizeli, P., Meyer Zu Schwabedissen, H. E., Liechti, M. E. · ACS Chemical Neuroscience (2018)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)
Szigeti, B., Nutt, D. J., Carhart-Harris, R. L. et al. · Scientific Reports (2023)
Poyatos, L., Lo Faro, A., Sprega, G. et al. · International Journal of Molecular Sciences (2022)
Ramaekers, J. G., Reckweg, J., Mason, N. L. et al. · Neuropsychopharmacology (2024)
Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)
Schmidt, E. F., Warner-Schmidt, J., Stogniew, M. et al. · Frontiers in Neuroscience (2024)
Jones, A., Warner-Schmidt, J., Kwak, H. et al. · JAMA Psychiatry (2026)